Tocilizumab reduced COVID-19 disease related adverse health outcomes
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome ...
Tag: Coronavirus
#VisualAbstract: Higher SARS-CoV-2 infection rate in pregnant patients
1. In Washington State, pregnant patients were found to be at a higher risk of SARS-CoV-2 infection. 2. Results were ...
Heterologous recombinant adenovirus-based COVID-19 vaccine (Gam-COVID-Vac) is tolerable and highly efficacious
1. Efficacy of the Gam-COVID-Vac (Sputnik V) vaccine against COVID-19 was 91.6%. 2. In the vaccine group, there were no ...
Novel SARS-CoV-2 vaccine candidate SCB-2019 offers good safety profile and elicits strong humoral responses
1. Novel SARS-CoV-2 vaccine SCB-2019 was well-tolerated amongst both younger and older adults. 2. SCB-2019 adjuvanted with AS03 or CpG/Alum ...
Dexamethasone decreased mortality in hospitalized COVID-19 patients
1. Patients hospitalized with COVID-19 and treated with dexamethasone showed an overall decrease in 28-day mortality compared to those treated ...
#VisualAbstract: Progression of COVID-19 reduced after high-titer convalescent plasma administration
1. Majority of the patients that received high-titer convalescent plasma within 72 hours of mild symptom onset were shown to ...
Azithromycin does not reduce mortality in patients hospitalized with COVID-19
1. All-cause mortality at 28 days was similar between patients in the azithromycin group and usual care alone group. 2. ...
#VisualAbstract: Positive Anti-Spike or Anti-Nucleocapsid Antibody Status is Associated with Reduced Incidence of SARS-CoV-2 Reinfection in Health Care Workers
1. Health care workers with anti-spike antibodies revealed no symptomatic infections during the follow-up period for at least six months. ...
Reduced risk of SARS-CoV-2 with presence of antibodies
1. Health care workers with anti-spike antibodies revealed no symptomatic infections during the follow-up period for at least six months. ...
#VisualAbstract: Tocilizumab not superior to standard care in randomized controlled trial for severe COVID-19 patients
1. Tocilizumab was not superior to standard care after 15 days, for COVID-19 patients in serious condition. 2. Patients given ...
